Can-Fite BioPharma Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CANF 2830 www.canfite.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Can-Fite BioPharma Ltd.

Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference - Nov 26th, 2025 5:00 am
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference - Nov 24th, 2025 5:00 am
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - Nov 20th, 2025 5:00 am
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Investors Await Clues on Fed's Interest Rate Cut - Nov 18th, 2025 6:49 am
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson - Nov 18th, 2025 5:00 am
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson - Sep 15th, 2025 5:00 am
Can-Fite Reports H1 2025 Financial Results and Clinical Update - Aug 28th, 2025 6:47 am
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone - Jul 30th, 2025 5:04 am
Can-Fite Announces Up To $15.0 Million Public Offering - Jul 28th, 2025 10:24 am
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia - Jul 28th, 2025 5:00 am
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston - Jun 16th, 2025 7:00 am
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis - May 5th, 2025 6:00 am
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients - Apr 17th, 2025 6:55 am
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares - Apr 14th, 2025 12:28 pm
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships - Apr 14th, 2025 6:30 am
Can-Fite Reports 2024 Financial Results and Clinical Update - Apr 14th, 2025 6:00 am
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Mar 28th, 2025 7:00 am
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol - Mar 24th, 2025 7:00 am
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market - Mar 20th, 2025 7:45 am
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson - Mar 19th, 2025 7:00 am